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ha reduction of 15% in composite primary cardiovascular
event rates.2-4 This creates the opportunity for further
improvement of clinical outcomes with non-LDL-based
approaches such as those that target high-density
lipoproteins (HDL) and vascular inflammation.5
In addition to their effect on reverse cholesterol
transport, HDL particles have anti-inflammatory, anti-
oxidative and anti-thrombotic effects.6 Whether these
HDL functions are altered in patients with established
cardiovascular disease or after an acute coronary
syndrome is not certain. However, despite raising HDL-
cholesterol, the cholesteryl ester transfer protein (CETP)
modulator dalcetrapib had a neutral overall effect on
cardiovascular events in the dal-Outcomes study.7
Dalcetrapib treatment also increased high-sensitivity C-
reactive protein by 18%, a seemingly paradoxical effect in
light of the anticipated action of HDL on inflammation.
This discrepancy between the potential cardio-protective
effects of HDL particles and the neutral dal-Outcomes
results as well as the unexpected pro-inflammatory effect
of dalcetrapib led us to hypothesize that sub-groups of
patients may respond differently to this medication.8
The pharmacogenomic analysis of dal-Outcomes
showed that the single nucleotide polymorphism
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influenced the effects of dalcetrapib on CV outcomes.9
Patients with the AA genotype benefited from a 39%
reduction in the primary composite cardiovascular
endpoint when treated with dalcetrapib compared to
placebo, AG heterozygotes had a neutral result, while
those with the GG genotype suffered a 25% increase in
risk.9 This pharmacogenomic analysis used a different
primary outcome measure than the parent clinical trial.
The pre-specified primary endpoint of the pharmacoge-
nomic analysis included coronary revascularization,
while the parent trial did not, in order to increase the
total number of events considered. Supporting ultraso-
nography data from the dal-Plaque-2 study showed
regression, stability and progression, respectively, of
carotid atherosclerosis for each of the three genotypes
(AA, AG and GG) in the dalcetrapib group.9 Concordant
findings were also obtained for the changes over time in
cholesterol efflux and systemic inflammation (as evaluat-
ed by high-sensitivity C-reactive protein).10 Indeed, the
significant increase in this inflammatory biomarker with
dalcetrapib occurred only in patients with the GG and AG
genotypes.
Interestingly, inactivation of Adcy9 in genetically-
modified mice protects from atherosclerosis and vascular
inflammation and improves endothelial function, but only
in the absence of CETP.11 The multiple observed
interactions between ADCY9 and CETP both in mice
and patients suggest that they represent a real biological
phenomenon and not a spurious statistical association.
Accordingly, we have designed and are conducting the
dal-GenE study to test prospectively the hypothesis that
dalcetrapib will have cardiovascular benefits when
administered to patients with the favorable genotype.
The study design and protocol are similar to those of dal-
Outcomes, except for the genetic inclusion criterion. We
describe and discuss the design of this study, as well as
the statistical and logistical considerations underpinning
this first large-scale cardiovascular precision medicine
trial targeting atherosclerotic disease.Methods
Study objectives
The primary study objective of dal-GenE is to prospec-
tively test the pharmacogenetic hypothesis that dalce-
trapib reduces CV morbidity and mortality (the
composite of CV death, resuscitated cardiac arrest, non-
fatal myocardial infarction (MI) and non-fatal stroke) in
participants with a documented recent acute coronary
syndrome (ACS) and the AA genotype at variant
rs1967309 in the ADCY9 gene. The secondary objective
is to assess the potential of dalcetrapib to reduce other
clinically important events, such as hospitalization for
ACS, unanticipated coronary revascularization and wors-
ening heart failure, in combination with the primaryendpoint. Additional objectives include the confirmation
of long-term safety, as well as effects on lipids, diabetes
and high sensitivity C-reactive protein.
Study design
dal-GenE is a double-blind, parallel group, placebo-
controlled randomized trial in patients recently hospital-
ized for ACS and confirmed to have the AA genotype at
variant rs1967309 in the ADCY9 gene. Participants are
enrolled across 819 investigational sites located in North
America, South America, Europe, Middle East, Africa,
Australia and New Zealand. All screened patients provide
written informed consent, duly reviewed and approved
by governing regulatory and ethics authorities before any
study-specific procedures are performed. Screening
procedures, comprised of ACDY9 genotyping conducted
at one of three regionally distributed laboratory testing
sites and the collection of demographic information, are
performed at the time of the index ACS event or anytime
thereafter, with the condition that randomization occurs
within the mandated window of 1-3 months after the
index event.
The investigational Cobas® ADCY9 Genotype CTA
system (Roche Molecular Systems Inc.) used for central-
ized and controlled genetic testing has been validated for
accuracy through comparisons with Sanger sequencing.
This is a real-time PCR test for the qualitative detection
and identification of the rs1967309 genotype in the
ADCY9 gene in DNA derived from whole blood. Genetic
testing results are available to the clinical research site
within 4 days of the blood draw.
Those subjects meeting the genetic testing criterion, all
other inclusion criteria and no exclusion criteria were
eligible for randomization. Eligible subjects were stabi-
lized on contemporary evidence-based medical care for
status post-ACS as individually prescribed by the treating
physician and completed all planned revascularization
procedures prior to randomization. A total of 6149
eligible patients have been randomized to 600 mg of
dalcetrapib or placebo daily in a 1:1 ratio. Patients
continue in the trial until the time at which approximate-
ly 582 primary events will have occurred and have been
positively adjudicated by an independent Clinical End-
point Committee (CEC). Subjects visit the clinic 1 and 6
months after randomization, and visits thereafter take
place every 6 months for efficacy and safety assessments
until completion of the trial.
Study population
A total of 44,990 patients with recent ACS have been
screened for this study in order to identify 6149
participants meeting the single genetic criterion and
other inclusion/no exclusion criteria required for ran-
domization, particularly given the overall prevalence of
AA genotype at rs1967309 in the ADCY9 gene of
approximately 20% in the general population.
Table I. Inclusion criteria
1. Both male and female subjects age 45 years and over at screening visit
2. Signed informed consent (approved by Institutional review Board (IRB)/Independent Ethics Committee (IEC)) obtained prior to any study specific screening
procedures
3. AA genotype at variant rs1967309 in the ADCY9 gene as determined by Cobas ADCY9 Genotype CTA testing, conducted at a designated investigational
testing site (ITS)
4. Clinically stable, i.e. free of ischemic symptoms at rest or with minimal exertion for at least 1 week prior to randomization
5. Prior to randomization, subject must have evidence of guidelines-based management of LDL-C, at a minimum to include medical and dietary treatment to a
target level of LDL-C b100 mg/dl (b2.6 mmol/L). Subjects with an LDL-C level ≥100 mg/dl (≥2.6 mmol/L) may be randomized if they cannot reach the
target goal of less than 100 mg/dl despite lipid-lowering regimen, or are unable to tolerate lipid-lowering regimen
6. Recently hospitalized for an acute coronary syndrome (between 1 and 3 months following the index event), defined as the occurrence of at least one of the
following events:
6.1 Myocardial infarction
6.1.1 Spontaneous myocardial infarction
A diagnosis of a qualifying MI event is defined by a rise and/or fall of cardiac biomarkers (preferably cardiac troponin) with at least one determination
greater than the 99th percentile upper reference limit (URL) plus at least one of the following described below:
6.1.1.1 Symptoms of myocardial ischemia, or
6.1.1.2 New or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle branch block, or
6.1.1.3 Development of pathological Q waves in the ECG, or
6. 1.1.4 Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality, or
6.1.1.5 Identification of an intracoronary thrombus by angiography
6.1.2 Procedure-Related Myocardial Infarction after Percutaneous Coronary Intervention (PCI)
A procedure-related MI after PCI is defined as an increase of cardiac troponin values with at least one determination greater than 5 times the 99th
percentile URL in patients with normal baseline values (less than or equal to 99th percentile URL) or a rise of cardiac troponin values N20% if the baseline
values are elevated and are stable or falling; plus at least one of the following described below:
• Symptoms suggestive of myocardial ischemia
• New ischemic ECG changes
• Imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality
• Angiographic findings consistent with a procedural complication
6.2 Hospitalization for ACS (ECG Abnormalities without Biomarkers):
A diagnosis of a qualifying ACS event without increases in cardiac biomarkers will require admission to hospital or emergency room (exceeding 23 h)
with symptoms presumed to be caused by myocardial ischemia with an accelerating tempo in the prior 48 hours and/or prolonged (at least 20 minutes) rest
chest discomfort and new ECG findings (or presumed new if no prior ECG available) as described below and at least one of the following:
• at least 50% stenosis of an epicardial coronary artery
• positive exercise or pharmacologic stress indicating reversible ischemia
• presence of pathologic Q-waves on ECG
Examples of new ECG findings include:
• New or presumed new ST depression of at least 0.5 mm in at least 2 contriguous leads or T wave inversion of at least 1 mm in leads with
predominant R wave or R/S N1 in at least 2 contriguous leads
• New or presumed new ST elevation at the J point in at least 2 contiguous leads with the following cut-off points: ≥0.2 mV in men and ≥0.15 mV in
women in leads V2-V3 and/or ≥0.1 mV in other leads or new or presumed new left bundle branch block (LBBB)
• New tall R wave of at least 40 ms in V1 and R/S ≥1 in V1 and/or V2 with concordant positive T wave in the absence of a conduction defect
• New Q waves ≥30 ms wide and at least 1 mm deep in any 2 leads of a contriguous lead grouping or Q wave N20 ms or QS complex in leads V2
and V3 (these criteria also apply to silent MI detected during a routine follow-up visit)
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a 1:1 ratio, stratified by region and the type of ACS index
event, to ensure equal numbers receive active treatment
and placebo in these strata.
All enrolled participants have presented with an ACS
event within the previous 1 to 3 months (Table I). In
addition, all patients (male and female) included in the
study are at least 45 years old, clinically stable, and have
evidence of guidelines-based management of LDL-C, at a
minimum including medical and dietary treatment to a
target level of LDL-C b100 mg/dL (b2.6 mmol/L). Patients
are excluded from participation in the trial for reasons of
safety and inability to successfully and compliantly
complete the trial as described in Table II. All participants
included in the study receive instructions on a heart healthy
diet, are counseled on appropriate life style modificationssuch as weight control, physical activity, and smoking
cessation and receive contemporary evidence-based med-
ical care for status post-ACS as individually prescribed by
the treating physician. (See Fig. 1.)
Study endpoints
The primary endpoint of this study is the time from
randomization to first occurrence of any component of
the composite endpoint, which includes CV death,
resuscitated cardiac arrest, non-fatal MI, and non-fatal
stroke, as positively adjudicated by the clinical endpoint
committee. Each component of the primary composite
endpoint will also be reported. The secondary endpoints
are the times from randomization to a) the composite of
the primary endpoint plus hospitalization for ACS
(with ECG abnormalities) or unanticipated coronary
Table II. Exclusion criteria
1. Females who are pregnant or breast-feeding
2. Women of childbearing potential (women who are not surgically sterile or postmenopausal defined as amenorrhea for N12 months) who are not using at
least one method of contraception
3. New York Heart Association (NYHA) Class III or IV heart failure
4. Last known hemoglobin b10 g/dL
5. Index ACS event presumed due to uncontrolled hypertension
6. Systolic blood pressure (BP) N180 mmHg and/or diastolic blood pressure N110 mmHg by the time of randomization despite anti-hypertensive therapy
7. Last known serum triglyceride level N500 mg/dL (N5.65 mmol/L) as assessed within 6 months prior to randomization
8. Last known hemoglobin A1c (HbA1c) N10% as assessed within 6 months prior to randomization
9. Subjects with clinically apparent liver disease, e.g., jaundice, cholestasis, hepatic synthetic impairment, or active hepatitis
10. Last known ALT or AST level N3 times the upper limit of normal (ULN) or last known alkaline phosphatase level N2 times the ULN as assessed within 6
months prior to randomization (excluding index event)
11. History of persistent and unexplained creatine phosphokinase (CPK) levels N3 times the ULN as assessed within 6 months prior to randomization
(excluding index event)
12. Last known serum creatinine N2.2 mg/dL (195 μmol/L) as assessed within 6 months prior to randomization
13. Previous exposure to anacetrapib or evacetrapib, or documented allergic reaction to any CETP inhibitor
14. History of malignancy (except for curatively treated basal cell or squamous cell carcinoma of the skin) during the 1 year prior to the screening
15. Any clinically significant medical condition that according to the investigator could interfere with the conduct of the study
16. Subjects whose life expectancy is shorter than 3 years
17. Presence of any last known laboratory value as evaluated prior to randomization that is considered by the investigator to potentially limit the patient’s
successful participation in the study
18. Current alcohol or drug abuse or history thereof within 2 years prior to screening that would likely interfere with compliance, based on investigator
assessment
19. Subjects who have received any investigational drug within 1 month of randomization, or who expect to participate in any other investigational drug or
device study during the conduct of this trial
20. Subjects unable or unwilling to comply with protocol requirements, or deemed by the investigator to be unfit for the study
21. Subjects who have undergone coronary artery bypass graft (CABG) between the index event and randomization
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endpoint plus hospitalization for new or worsening heart
failure (Table III). Exploratory endpoints include changes
from baseline to 6 months in blood levels of lipid sub-
fractions and high-sensitivity C-reactive protein. Treat-
ment safety, including effects on diabetes, is evaluated
through the assessment of adverse events and laboratory
measurements.
Sample size calculation
The target sample size of 6000 randomized participants
was calculated assuming an expected relative risk reduction
of 22% and a statistical significance defined as a two-sided
alpha of 0.05. The trial will have 85% power when 582
patients have experienced a positively adjudicated primary
event in the combined treatment groups assuming a 2.8-year
recruitment period, a 1% yearly lost to follow-up rate, and a
7% event rate at 2 years following randomization to the
placebo group. In this event-driven trial, the minimum
detectable effect of dalcetrapib compared to placebo at
study end will be 15%.
Statistical analyses
The analyses will be performed on the intention-to-treat
population, which includes all randomized patients. A
stratified Cox proportional hazards model will be used to
analyze the primary endpoint. Time to event will start at
randomization and subjects who are lost to follow-up
(while event-free) will be censored at the time that they
are last known to be event-free. The null (H0) andalternative (HA) hypotheses to be tested with the above
Cox model are H0: λ = 1 versus HA: λ ≠ 1 where λ is the
assumed constant hazard ratio for the time to occurrence
of the composite events of the primary endpoint for the
dalcetrapib and placebo groups. The hazard ratio, within
strata, will be assumed to depend on treatment alone. The
analyses will be conducted at the 0.05 significance level.
Secondary endpoints are expressed as time to event
and analyses similar to that for the primary endpoint will
be conducted. The changes from baseline in lipid sub-
fractions and high-sensitivity C-reactive protein levels will
be compared between treatment groups using an analysis
of covariance adjusting for baseline value and for the two
stratification factors, ACS index event type and region.
Estimates of treatment effect will be presented with 95%
confidence intervals and P-values.
In order to control the type I error that results from the
multiplicity of endpoints, the secondary endpoints will be
formally tested using theHochberg’s step-up procedure only
if the primary analysis results in significant treatment effect at
P b .05. Otherwise, statistical tests for the secondary
endpoints will be presented solely for illustrative purposes.
The primary and secondary efficacy endpoints will also
be evaluated within subgroups of subjects using Cox
proportional hazards models, adding to the models a term
for the factor defining the subgroup and a term for the
interaction between the factor and the treatment group.
This interaction term will be tested at the 0.1 significance
level and will determine whether the treatment effect is
affected by the presence of the factor. In addition, under
Figure 1
Design of the dal-GenE trial.
Table III. Primary and secondary efficacy endpoints
Primary endpoint:
• Time from randomization to the first occurrence of any component of the composite endpoint which includes CV death, resuscitated cardiac arrest, non-fatal
MI and non-fatal stroke, as positively adjudicated by the clinical endpoint committee
• Each component of the primary composite endpoint will also be reported
Secondary endpoints:
• Time from randomization to the first occurrence of CV death, resuscitated cardiac arrest, non-fatal MI, non-fatal stroke, or hospitalization for ACS (with ECG
abnormalities) or unanticipated coronary revascularization
• Time from randomization to the first occurrence of CV death, resuscitated cardiac arrest, non-fatal MI, non-fatal stroke, or hospitalization for new or
worsening heart failure
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estimated and presented with 95% confidence intervals
within subgroups.
A futility analysis will be conducted by the independent
Data Safety Monitoring Board (DSMB), which will
determine if there is sufficient evidence of efficacy to
justify continuation of the trial to its completion. This
futility assessment, performed when approximately 70%
of the target number of patients with a first positively
adjudicated primary endpoint is reached (which corre-
sponds to 407 patients), will be based on the conditional
power of the trial derived under various relative risk
reduction assumptions.
In order to characterize further the potential treatment
effect, an analysis of the primary endpoint will be
conducted with the hazard ratio assumed to depend on,
in addition to study treatment, the potentially prognostic
factor of baseline HDL-C. The latter will be included in the
stratified Cox proportional hazards model used for the
primary analysis to provide an estimate of treatment
effect that adjusts for HDL-C at baseline. Treatments will
also be examined with respect to the incidence of
adverse events, serious adverse events and adverse events
leading to premature study withdrawal or dose modifica-tions. Adverse events will be grouped and summarized by
body system as defined by the latest version of the
Medical Dictionary for Regulatory Activities (MedDRA),
following classification of investigator assessments into
MedDRA preferred terms.
The dal-GenE study is funded by DalCor Pharmaceuti-
cals. The authors are solely responsible for the design of
the study, all study analyses, the drafting and editing of
the paper and its final contents.Discussion
The consistent ADCY9 genotype-dependent effects of
the CETP inhibitor dalcetrapib on CV clinical outcomes,
carotid atherosclerosis, cholesterol efflux and high-
sensitivity C-reactive protein formed the basis for the
launch of the dal-GenE randomized controlled trial.8-10
Further evidence of an interplay between these two gene
products was obtained from genetically-modified mice,
with ADCY9 inactivation clearly protecting from athero-
sclerosis and vascular inflammation and improving
endothelial function in the absence of CETP.11
A genotype-dependent result was also reported with
the CETP inhibitor evacetrapib, albeit with a smaller
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associated with that case-control analysis.12 Indeed, one
of the concerns was that the secondary analysis did not
involve random selection of control subjects.13 Never-
theless, a meta-analysis of the dalcetrapib and evacetrapib
data yielded a relative risk reduction of 20% in CV event
rates when patients with the AA genotype at rs1967309
received the CETP inhibitor compared to placebo.14 In
contrast, the effects of anacetrapib were not affected by
ADCY9 genotype in REVEAL.15, 16 The differences in
chemical structures, binding sites and functional effects
of dalcetrapib and anacetrapib may at least in part explain
the different pharmacogenomic results.17 The strong
CETP inhibition caused by anacetrapib reduces the
fractional clearance rate of HDL’s ApoA-I18 and physio-
logically resembles complete CETP deficiency with its
very large HDL particles.19 In contrast, dalcetrapib causes
partial CETP modulation of heterotypic transfer of
cholesteryl esters between HDL and Apo-B containing
lipoproteins, without affecting homotypic transfers
between HDL particles.20
The different populations treated with dalcetrapib in
dal-Outcomes7 and anacetrapib in REVEAL (15) – 100%
and 0% of patients with recent ACS respectively – might
also have affected the results.
While anacetrapib induced a significant 10% relative
risk reduction in the overall REVEAL study, its accumu-
lation in fat for more than 5 years led the manufacturer to
discontinue its clinical development.16 In contrast, the
safety and tolerability profile of dalcetrapib has been
demonstrated with the dosage (600 mg daily) beyond
which no additional pharmacodynamic benefit is obtain-
ed.21 Accordingly, the same dosage of dalcetrapib is used
in dal-GenE.
Although the analysis of patient subgroups in clinical
trials is notoriously fraught with hazard, the specific
group of responsive patients identified in previous
dalcetrapib studies is defined by genotype and not
based on a reversible, less definitive, phenotype.
Nevertheless, these hypothesis-generating results require
confirmation in a large study. The sample size of 6149
patients in the CV event-driven dal-genE study will allow
the detection of a 15% relative risk reduction with
statistical significance. This assumes a primary endpoint
rate of 7% at 2 years in the placebo group based in part on
dal-Outcomes, but the incidence of the myocardial
infarction component could likely be higher in dal-GenE
compared to the previous dal-Outcomes study because of
current widespread use of the high-sensitivity troponin
assay in clinical practice. The effect size of dalcetrapib in
patients with the AA genotype deserves discussion.
Although a relative risk reduction of 39% was observed
with dalcetrapib in the dal-Outcomes discovery cohort,9
this result may have been inflated by the so-called
winner’s curse, or overestimation of effect size, in initial
genetic studies. As previously mentioned, a meta-analysisof pharmacogenomic results of dalcetrapib and evace-
trapib yielded a 20% improvement of CV outcomes with
CETP inhibition.14 In light of the recently observed
relative risk reduction of 15% in the composite primary
endpoint of large-scale trials with injectable PCSK9
inhibitors,2-4 we believe that a similar benefit obtained
with oral dalcetrapib treatment on a background of
standard-of-care therapies would be clinically relevant.
The dal-GenE study also represents the first combined
clinical development of a new anti-atherosclerosis
therapy and its companion diagnostic test. This diagnos-
tic has been carefully tested prior to utilization in the
clinical trial and is robust, and the evaluation was
submitted to the authorities as part of the investigational
device exemption. The risk of an incorrect result of this
genetic test is less than 1 in 70,000, and this will further
decrease with additional assessments over time. This is
particularly important because of the increased risk
associated with treating patients with the GG genotype.
Genetic testing was performed at three central laborato-
ries (including the University of Montreal Beaulieu-
Saucier Pharmacogenomics Center), and results were
provided within 4 days of blood draw for the approxi-
mately 44,990 patients screened in 31 countries. The
execution of the dal-GenE study attests to the feasibility of
performing large international pharmacogenetics-guided
CV clinical trials. The importance of this demonstration
lies in the emergence of precision medicine to optimize
efficacy by tailoring treatment strategies to personal
patient characteristics, and the necessary randomized
controlled trials to prove the value of such approaches.
The widespread adoption of genotyping by local research
teams and participants was better than anticipated,
which supports the fact that the cardiovascular field is
ready for pharmacogenetic strategies.
In conclusion, the dal-GenE study is the first pharma-
cogenetic randomized trial targeting the reduction of
cardiovascular events in patients with a recent acute
myocardial infarction and a specific genotype. It is fully
recruited and the results are expected by early 2021.Disclosures
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